Lexeo Therapeutics (LXEO) Projected to Announce Quarterly Earnings on Thursday

Lexeo Therapeutics (NASDAQ:LXEO) is projected to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, August 17, 2026 at 9:30 AM ET.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. On average, analysts expect Lexeo Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lexeo Therapeutics Trading Down 3.7%

Shares of LXEO opened at $4.63 on Tuesday. The stock’s 50-day moving average price is $4.62 and its two-hundred day moving average price is $5.69. Lexeo Therapeutics has a 12 month low of $3.99 and a 12 month high of $10.99. The company has a market capitalization of $363.55 million, a PE ratio of -3.19 and a beta of 1.46.

Insider Buying and Selling at Lexeo Therapeutics

In related news, insider Narinder Pal Bhalla sold 22,306 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total transaction of $98,592.52. Following the transaction, the insider owned 82,194 shares in the company, valued at $363,297.48. The trade was a 21.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total transaction of $116,242.56. Following the transaction, the chief executive officer directly owned 377,817 shares in the company, valued at approximately $1,692,620.16. This represents a 6.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 62,204 shares of company stock valued at $280,089 in the last quarter. 2.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Lexeo Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company bought a new stake in Lexeo Therapeutics in the 4th quarter valued at about $190,000. Police & Firemen s Retirement System of New Jersey grew its stake in Lexeo Therapeutics by 171.1% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 16,373 shares of the company’s stock valued at $163,000 after acquiring an additional 10,333 shares during the period. Intech Investment Management LLC increased its holdings in shares of Lexeo Therapeutics by 19.5% during the fourth quarter. Intech Investment Management LLC now owns 14,188 shares of the company’s stock valued at $141,000 after acquiring an additional 2,317 shares in the last quarter. Brevan Howard Capital Management LP bought a new stake in shares of Lexeo Therapeutics during the third quarter valued at approximately $122,000. Finally, Bank of America Corp DE raised its position in shares of Lexeo Therapeutics by 6.1% during the third quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock worth $188,000 after purchasing an additional 1,626 shares during the period. Institutional investors own 60.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Chardan Capital upgraded Lexeo Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. JPMorgan Chase & Co. decreased their target price on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, June 25th. Finally, Weiss Ratings lowered shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Lexeo Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $18.75.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical?stage biotechnology company dedicated to developing novel, precision?designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next?generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.